Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral topotecan in advanced non-small cell lung cancer
NCT00049998Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2001
- Primary completion
- Apr 2004
- Modality
- Small Molecules
- Countries
- 31
01
Overview
Phase 3, randomised, open-label trial of topotecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by GSK. Primary endpoint: One-year survival rate at 1 year. Started Oct 2001; status: completed.
02
Drugs
topotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00049998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00049998.